Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Pfizer’s Lyrica Gains U.S. Approval for Spinal Pain

Lyrica, seen here, is Pfizer’s best-selling drug after cholesterol pill Lipitor. Photographer: JB Reed/Bloomberg
Lyrica, seen here, is Pfizer’s best-selling drug after cholesterol pill Lipitor. Photographer: JB Reed/Bloomberg

June 21 (Bloomberg) -- Pfizer Inc.’s second-best selling drug, Lyrica, was approved by U.S. regulators today for use against pain caused by spinal cord injuries.

The Food and Drug Administration cleared the expanded use of Lyrica, already backed to treat nerve pain from fibromyalgia, diabetic nerve pain and pain after shingles, New York-based Pfizer, said today in a statement. Pfizer estimates a potential patient population size of about 100,000 people.

“Until now, no FDA approved treatment options were available in the U.S. for people with neuropathic pain associated with spinal cord injury, a condition which can be extremely disabling,” said Steven J. Romano, senior vice president and head of Pfizer’s medicines development group, Global Primary Care business unit, in the statement.

Lyrica is Pfizer’s best-selling drug after cholesterol pill Lipitor, which lost patent protection in November. It had $3.39 billion in revenue last year. The treatment has patent protection until 2018, and Pfizer is working to expand its use.

Pfizer declined less than 1 percent to $22.60 at the close in New York.

To contact the reporters on this story: Drew Armstrong in New York at darmstrong17@bloomberg.net; Catherine Larkin in Denver at clarkin4@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.